Huiyu Pharmaceutical (688553.SH) products have obtained approval for overseas listing.
Huiyu Pharmaceutical (688553.SH) announced that its subsidiaries Seacross (Europe) Pharma Ltd. and Seacross Pharmaceuticals Ltd. have recently received approval for the marketing of company products including injection of Teicoplanin, injection of Paclitaxel (albumin-bound) and Injection of Octreotide Acetate from the German Federal Institute for Drugs and Medical Devices, Spanish Agency of Medicines and Medical Devices, Belgian Federal Agency for Medicines and Health Products, Pakistan Drug Regulatory Authority and Ministry of Health.
Huayu Pharmaceuticals (688553.SH) announced that its subsidiaries Seacross (Europe) Pharma Ltd. and Seacross Pharmaceuticals Ltd. have recently received marketing authorization for the company's injection products, including tapentadol for injection, paclitaxel for injection (albumin bound), and octreotide acetate injection, from the German Federal Institute for Drugs and Medical Devices, the Spanish Agency for Medicines and Medical Devices, the Belgian Federal Agency for Medicines and Health Products, the Drug Regulatory Authority of Pakistan, and the Ministry of Health.
The company's research and development of these injection products have obtained marketing authorization in Germany, Spain, Belgium, and Pakistan, which will enrich the company's product pipeline in the international market, enhance its brand image, and continue to expand the breadth and depth of international business, further consolidating the foundation for sustainable development in the international market.
Related Articles
RELIANCE GLO HL (00723) is expected to achieve other income from listed securities investments of approximately HK$61.6 million in the fiscal year 2026, representing a year-on-year increase of approximately 16.74 times.
CITIC SEC (06030) released its first quarter performance report with a net profit attributable to shareholders of 10.216 billion yuan, an increase of 54.6% year-on-year.
SBP GROUP (01177): Naltrexone sustained-release tablets "peripheral -opioid receptor antagonist" approved for listing in the Greater Bay Area
RELIANCE GLO HL (00723) is expected to achieve other income from listed securities investments of approximately HK$61.6 million in the fiscal year 2026, representing a year-on-year increase of approximately 16.74 times.
CITIC SEC (06030) released its first quarter performance report with a net profit attributable to shareholders of 10.216 billion yuan, an increase of 54.6% year-on-year.
SBP GROUP (01177): Naltrexone sustained-release tablets "peripheral -opioid receptor antagonist" approved for listing in the Greater Bay Area
